NKTR — Nektar Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $2.07bn
- $1.89bn
- $55.23m
Annual cashflow statement for Nektar Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -524 | -368 | -276 | -119 | -164 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 120 | 48 | 95.6 | -54.9 | -8.45 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -23.1 | 0.492 | -19.8 | -6.24 | -37 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -413 | -304 | -193 | -176 | -209 |
| Capital Expenditures | -15 | -5.68 | -0.865 | -1.47 | -0.868 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 218 | 372 | 140 | 144 | -0.329 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 203 | 366 | 140 | 143 | -1.2 |
| Financing Cash Flow Items | 3 | 0.75 | 0 | 15 | -1.15 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 36.2 | 1.51 | 0.03 | 42.1 | 181 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -174 | 63 | -53 | 8.97 | -29.1 |